PMEF
AMRX icon

Point72 Middle East FZE’s Amneal Pharmaceuticals AMRX Stock Holding History

Point72 Middle East FZE’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-4,780
Closed -$6.64K – 1521
2023
Q1 		$6.64K Sell
4,780
-7,052
-60% -$14K ﹤0.01% 1504
2022
Q4 		$23.5K Buy
+11,832
New +$26.5K ﹤0.01% 1601

Other funds holding AMRX

FI
Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Point72 Middle East FZE's AMRX Position: Q2 2023 in Review

Point72 Middle East FZE sold out of Amneal Pharmaceuticals (AMRX) in Q2 2023, closing a stake of 4,780 shares — an estimated $6.64K sold.

Point72 Middle East FZE first reported a position in AMRX in Q4 2022 and held it in 2 quarters. The position peaked at $23.5K in Q4 2022. 128 funds tracked by Wall St. Rank hold AMRX as of Q2 2023.

  • Point72 Middle East FZE reported no remaining Amneal Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 4,780 Amneal Pharmaceuticals shares in Q2 2023, an estimated $6.64K.
  • Point72 Middle East FZE first reported a position in Amneal Pharmaceuticals in Q4 2022 and held it in 2 quarters.
  • Point72 Middle East FZE's Amneal Pharmaceuticals position peaked at $23.5K in Q4 2022.
  • 128 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2023.

Based on Point72 Middle East FZE's 13F filing for Q2 2023, filed 14 Aug 2023.